Adlai Nortye Group (ANL) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Rigel Pharmaceuticals (RIGL) over the past year, gaining 712.1% versus a gain of 62.7%. Adlai Nortye Group is the larger company by market cap ($904.8 million vs $896.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | RIGL |
|---|---|---|
| Share price | $14.05 | $47.99 |
| Market cap | $904.79M | $896.45M |
| 1-day change | -2.84% | +4.08% |
| YTD return | +889.44% | +12.05% |
| 1-year return | +712.14% | +62.68% |
| 5-year return | — | +41.98% |
| P/E ratio (TTM) | — | 2.84 |
| Forward P/E | — | 9.72 |
| EPS (TTM) | $-0.66 | $16.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $52.24 |
| 52-week low | $0.879 | $24.95 |
| Distance from 52-week high | -18.55% | -8.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +109.96% | +31.28% |
| Average volume | 176.53K | 291.58K |
| Shares outstanding | 58.73M | 18.68M |
| Employees | 109 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed RIGL by 649.5 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 172 employees
ANL vs RIGL FAQ
Which is bigger, Adlai Nortye Group or Rigel Pharmaceuticals?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $904.79M compared with $896.45M for Rigel Pharmaceuticals (RIGL).
Which stock has performed better over the past year, ANL or RIGL?
ANL returned +712.14% over the past 12 months, compared with +62.68% for RIGL (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.